The k-Tetranacci Sequences

Bu tez çalışmasında, Tetranacci dizisi, k-Tetranacci dizisi biçiminde genelleştirilmiş ve geçmiş çalışmalarda bulunan eşitlikler bu genelleştirme için incelenmiştir. k-Tetranacci matrisi tanımlanmış ve bu matris yardımıyla k-Tetranacci dizisi için bazı eşitlikler bulunmuştur.In this thesis, the Tetranacci sequence was generalized as the k-Tetranacci sequence and the equations which were discovered in the past studies, were examined for this generalization. The k-Tetranacci matrix was defined and some equations were discovered with the help of this matrix

Shigella flexneri Bacteremia in a Patient with Behcet’s Disease and Receiving Immunosuppressive Treatment: A Case Report

Shigella bacteremia usually causes gastrointestinal infections and has a table of disease accompanied by abdominal pain, bloody diarrhoea and fever. Bacteremia is not a common case but develops in the children under two years age and in malnourished children. Shigella bacteremia has a high rate of mortality and is a rare complication in adults which usually occurs in the presence of predisposing factors as diabetes and steroid use. In this study we presented a case, who had Behçet’s disease and received immunosuppressive treatment, developed S. flexneri bacteremia at the age of 56

Serum Level of suPAR and YKL-40, a New Biomarker in Patients with Acute Myocardial Infarction?

Introduction: Low grade inflammation plays an important role in the several development process of coronary artery disease. The soluble urokinase plasminogen activator receptor (suPAR) and chitinase 3-like protein 1 (YKL-40) are the new potential biomarkers of inflammation. We intended to test the hypothesis whether the inflammatory biomarker YKL-40 alone or in combination with suPAR could be the new diagnostic biomarkers for acute myocardial infarction (AMI). Material and Methods: Fifty-five patients with AMI and seventy control subjects were included in the study. The diagnosis of AMI was based on the current 3rd standard universal definition criteria. Serum YKL-40 and suPAR levels were measured at the first and second days of AMI by using ELİSA method. Results: Serum YKL-40 levels were significantly higher in the first (69.10±16.58 ng/mL) and second day (60.64±16.01 ng/mL) of AMI patients than those of the control subjects (37.11±4.30 ng/mL) (p>0.001). Serum YKL-40 levels in the first day of AMI patients also were significantly higher than those of second day of AMI patients (p>0.01). Serum suPAR were significantly higher in the first (6.58±3.24 ng/mL) and second day (5.86±4.56 ng/mL) of AMI patients than those of the control subjects (2.26±1.92 ng/mL) (p>0.001). Conclusion: Serum suPAR and YKL-40 can be considered strong inflammatory markers of AMI. We concluded that serum suPAR and YKL-40 levels at the first day and second day of AMI could be used as a clinically useful marker for diagnosis of AMI